Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection

Vaccine

Volumn 30, Issue 2, 2012, Pages 350-360

  Brown, Tyler H T ^a   David, Jason ^a   Acosta Ramirez, Elizabeth ^a   Moore, Jessica M ^a   Lee, Song ^a   Zhong, Guangming ^b   Hancock, Robert E W ^c   Xing, Zhou ^d   Halperin, Scott A ^a   Wang, Jun ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Adenovirus; Adjuvant; Chlamydia; CPAF; CpG; Heterologous prime boost; HH2; Homologous prime boost; Th1; Th17; Vaccination

Indexed keywords

ADENOVIRUS VECTOR; CPG OLIGODEOXYNUCLEOTIDE; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CHLAMYDIA; CHLAMYDIASIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH17 CELL;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; CHLAMYDIA MURIDARUM; DRUG CARRIERS; FEMALE; GENETIC VECTORS; IMMUNIZATION, SECONDARY; LYMPHOCYTES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; REPRODUCTIVE TRACT INFECTIONS; VACCINATION; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84355161518     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.086     Document Type: Article

References (49)

1. Brunham R.C., Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat Rev Immunol 2005, 5(2):149-161.
2. Gottlieb S.L., Martin D.H., Xu F., Byrne G.I., Brunham R.C. Summary: the natural history and immunobiology of Chlamydia trachomatis genital infection and implications for Chlamydia control. J Infect Dis 2010, 201(SUPPL. 2):S190-S204.
3. Farris C.M., Morrison S.G., Morrison R.P. CD4+ T cells and antibody are required for optimal MOMP vaccine induced immunity to Chlamydia muridarum genital infection. Infect Immun 2010, 78(10):4374-4383.
4. Ito J.I., Lyons J.M. Role of gamma interferon in controlling murine chlamydial genital tract infection. Infect Immun 1999, 67(10):5518-5521.
5. Johansson M., Schon K., Ward M., Lycke N. Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin A response. Infect Immun 1997, 65(3):1032-1044.
6. Li W., Murthy A.K., Guentzel M.N., Seshu J., Forsthuber T.G., Zhong G., et al. Antigen-specific CD4+ T cells produce sufficient IFN-{gamma} to mediate robust protective immunity against genital Chlamydia muridarum infection. J Immunol 2008, 180(5):3375-3382.
7. Gondek D.C., Roan N.R., Starnbach M.N. T Cell responses in the absence of IFN-{gamma} exacerbate uterine infection with Chlamydia trachomatis. J Immunol 2009, 183(2):1313-1319.
8. Zhou X., Chen Q., Moore J., Kolls J.K., Halperin S., Wang J. Critical role of the interleukin-17/interleukin-17 receptor axis in regulating host susceptibility to respiratory infection with Chlamydia species. Infect Immun 2009, 77(11):5059-5070.
9. Shavlakadze N., Gorgoshidze B. IL-17/IL-23 and Chlamydia trachomatis. Georgian Med News 2010, 183:45-51.
10. Zhang X., Gao L., Lei L., Zhong Y., Dube P., Berton M.T., et al. A MyD88-dependent early IL-17 production protects mice against airway infection with the obligate intracellular pathogen Chlamydia muridarum. J Immunol 2009, 183(2):1291-1300.
11. Bai H., Cheng J., Gao X., Joyee A.G., Fan Y., Wang S., et al. IL-17/Th17 promotes type 1 T cell immunity against pulmonary intracellular bacterial infection through modulating dendritic cell function. J Immunol 2009, 183(9):5886-5895.
12. Jiang X., Shen C., Yu H., Karunakaran K.P., Brunham R.C. Differences in innate immune responses correlate with differences in murine susceptibility to Chlamydia muridarum pulmonary infection. Immunology 2010, 129(4):556-566.
13. Paris R.M., Kim J.H., Robb M.L., Michael N.L. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev Vaccines 2010, 9(9):1055-1069.
14. Vemula S.V., Mittal S.K. Production of adenovirus vectors and their use as a delivery system for influenza vaccines. Expert Opin Biol Ther 2010, 10:1469-1487.
15. Hill A.V., Reyes-Sandoval A., O'Hara G., Ewer K., Lawrie A., Goodman A., et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 2010, 6(1):78-83.
16. Xing Z., Lichty B.D. Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis 2005, 86(3-4):211-217.
17. Santosuosso M., Zhang X., McCormick S., Wang J., Hitt M., Xing Z. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. J Immunol 2005, 174(12):7986-7994.
18. Wang J., Thorson L., Stokes R.W., Santosuosso M., Huygen K., Zganiacz A., et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 2004, 173(10):6357-6365.
19. Song K., Bolton D.L., Wei C.J., Wilson R.L., Camp J.V., Bao S., et al. Genetic immunization in the lung induces potent local and systemic immune responses. Proc Natl Acad Sci U S A 2010, 107(51):22213-22218.
20. Park K.S., Lee J., Ahn S.S., Byun Y.H., Seong B.L., Baek Y.H., et al. Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge. Virology 2009, 395(2):182-189.
21. Kim S., Jang J.E., Yu J.R., Chang J. Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection. Vaccine 2010, 28(22):3801-3808.
22. Gallichan W.S., Rosenthal K.L. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine 1995, 13(16):1589-1595.
23. Gallichan W.S., Rosenthal K.L. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J Exp Med 1996, 184(5):1879-1890.
24. Wang J., Xing Z. Tuberculosis vaccines: the past, present and future. Expert Rev Vaccines 2002, 1(3):341-354.
25. Zygmunt B.M., Rharbaoui F., Groebe L., Guzman C.A. Intranasal immunization promotes Th17 immune responses. J Immunol 2009, 183(11):6933-6938.
26. Thorner A.R., Vogels R., Kaspers J., Weverling G.J., Holterman L., Lemckert A.A., et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microbiol 2006, 44(10):3781-3783.
27. Kindrachuk J., Jenssen H., Elliott M., Townsend R., Nijnik A., Lee S.F., et al. A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. Vaccine 2009, 27(34):4662-4671.
28. Cao D., Li H., Jiang Z., Xu C., Cheng Q., Yang Z., et al. Synthetic innate defence regulator peptide enhances in vivo immunostimulatory effects of CpG-ODN in newborn piglets. Vaccine 2010, 28(37):6006-6013.
29. Schellack C., Prinz K., Egyed A., Fritz J., Wittmann B., Ginzler M., et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 2006, 24(26):5461-5472.
30. Kovacs-Nolan J., Latimer L., Landi A., Jenssen H., Hancock R.E.W., Babiuk L.A., et al. The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice. Vaccine 2009, 27(14):2055-2064.
31. Mookherjee N., Brown K.L., Bowdish D.M.E., Doria S., Falsafi R., Hokamp K., et al. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 2006, 176(4):2455-2464.
32. Dong F., Zhong Y., Arulanandam B., Zhong G. Production of a proteolytically active protein, chlamydial protease/proteasome-like activity factor, by five different Chlamydia species. Infect Immun 2005, 73(3):1868-1872.
33. Shaw A.C., Vandahl B.B., Larsen M.R., Roepstorff P., Gevaert K., Vandekerckhove J., et al. Characterization of a secreted Chlamydia protease. Cell Microbiol 2002, 4(7):411-424.
34. Zhong G., Fan P., Ji H., Dong F., Huang Y. Identification of a Chlamydial protease-like activity factor responsible for the degradation of host transcription factors. J Exp Med 2001, 193(8):935-942.
35. Ng P., Graham F.L. Construction of first-generation adenoviral vectors. Methods Mol Med 2002, 69:389-414.
36. Wang J., Snider D.P., Hewlett B.R., Lukacs N.W., Gauldie J., Liang H., et al. Transgenic expression of granulocyte-macrophage colony-stimulating factor induces the differentiation and activation of a novel dendritic cell population in the lung. Blood 2000, 95(April 1 (7)):2337-2345.
37. Chen L., Wang J., Zganiacz A., Xing Z. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect Immun 2004, 72(1):238-246.
38. Wang J., Palmer K., Lotvall J., Milan S., Lei X.F., Matthaei K.I., et al. Circulating, but not local lung, IL-5 is required for the development of antigen-induced airways eosinophilia. J Clin Invest 1998, 102(6):1132-1141.
39. Wang J., Zganiacz A., Xing Z. Enhanced immunogenicity of BCG vaccine by using a viral-based GM-CSF transgene adjuvant formulation. Vaccine 2002, 20(23-24):2887-2898.
40. Mu J., Jeyanathan M., Small C.L., Zhang X., Roediger E., Feng X., et al. Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis. Mol Ther 2009, 17(6):1093-1100.
41. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008, 8(5):337-348.
42. Reiner S.L. Development in motion: helper T cells at work. Cell 2007, 129(1):33-36.
43. O'Connor W., Kamanaka M., Booth C.J., Town T., Nakae S., Iwakura Y., et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 2009, 10(6):603-609.
44. Awasthi A., Kuchroo V.K. IL-17A directly inhibits TH1 cells and thereby suppresses development of intestinal inflammation. Nat Immunol 2009, 10(6):568-570.
45. Lin Y., Ritchea S., Logar A., Slight S., Messmer M., Rangel-Moreno J., et al. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 2009, 31(5):799-810.
46. Kaufman D.R., Bivas-Benita M., Simmons N.L., Miller D., Barouch D.H. Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes. J Virol 2010, 84(12):5986-5996.
47. Gallichan W.S., Woolstencroft R.N., Guarasci T., McCluskie M.J., Davis H.L., Rosenthal K.L. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol 2001, 166(5):3451-3457.
48. Li Z., Zhang M., Zhou C., Zhao X., Iijima N., Frankel F.R. Novel vaccination protocol with two live mucosal vectors elicits strong cell-mediated immunity in the vagina and protects against vaginal virus challenge. J Immunol 2008, 180(4):2504-2513.
49. Morrison S.G., Morrison R.P. A predominant role for antibody in acquired immunity to Chlamydial genital tract reinfection. J Immunol 2005, 175(11):7536-7542.